ArcticZymes presents joint poster with the Cell and Gene Therapy Catapult

SAN HQ developed by ArcticZymes has quickly found its place as a valuable tool in manufacture of gene-delivery vehicles (viral vectors) applicable in gene therapy. In cooperation with the Cell and Gene Therapy Catapult, a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK, ArcticZymes presented a scientific poster at the “Cell Therapy Manufacturing & Gene Therapy Congress 2019” in Amsterdam December 3rd–6th. The poster describes why SAN HQ is such an effective tool in the removal of DNA impurities from viral vectors in the manufacturing process. In brief, DNA impurities are more accessible as salt concentration is increased, this coincides with SAN HQ’s optimal performance characteristics. The result is an increase in the efficiency of DNA removal and a decrease in the time to manufacture.

The Cell and Gene Therapy Catapult is supported by Innovate UK to assist cell and gene therapy organizations across the world to translate early stage research into commercially viable solutions. ArcticZymes is proud to work with such a renowned leader in the Gene therapy field and to demonstrate the unique properties ArcticZymes nuclease portfolio brings to the Gene therapy field.